Vyleesi Pharmacokinetics (ADME): How Bremelanotide Is Absorbed, Distributed, Metabolized, and Eliminated

The Short Version: What ADME Means for Vyleesi

ADME describes absorption, distribution, metabolism, and excretion. For Vyleesi, the practical sequence is straightforward: the subcutaneous injection is absorbed rapidly and nearly completely, a relatively small proportion binds to serum protein, the peptide is broken down through hydrolysis, and most recovered radioactivity appears in urine. The current FDA label supplies the key human pharmacokinetic values.

Several older values previously shown on this page were not the values in the current label. The corrected figures are Cmax 72.8 ng/mL rather than 80.3 ng/mL, volume of distribution 25.0 L rather than 20.4 L, and clearance 6.5 L/hour rather than 47.8 L/hour. Those are not rounding differences. They materially change how the drug's disposition is described.

Pharmacology Before Pharmacokinetics

Vyleesi is a melanocortin receptor agonist. According to the FDA clinical pharmacology section, bremelanotide activates several melanocortin receptor subtypes, with MC1R and MC4R binding most relevant at therapeutic exposure. MC4R-expressing neurons are present in multiple areas of the central nervous system, while MC1R is expressed on melanocytes and is connected to melanin production.

The label is careful about what is known: the mechanism by which Vyleesi improves hypoactive sexual desire disorder (HSDD) is unknown. It is therefore too strong to say that the drug's clinical effect has been proved to result from direct action in a particular hypothalamic nucleus, or that clinical adverse effects prove a specific degree of blood-brain-barrier penetration.

The two 24-week RECONNECT trials evaluated clinical efficacy and safety in 1,247 premenopausal women with acquired, generalized HSDD. Bremelanotide improved the co-primary desire and distress measures more than placebo, but the trials were not a concentration-response study and do not establish a plasma threshold at which sexual desire begins [1].

Absorption: Subcutaneous Bioavailability and Time to Peak

After subcutaneous Vyleesi, median plasma Tmax is approximately 1 hour, with a reported range of 0.5 to 1 hour. Absolute bioavailability is about 100%. Injection into the abdomen versus the thigh did not significantly affect systemic exposure in the current prescribing information.

Following subcutaneous administration, the reported mean Cmax is 72.8 ng/mL and mean AUC is 276 hour-ng/mL. Plasma concentrations rise in a less than dose-proportional manner over the studied 0.3 to 10 mg range, with mean Cmax reaching a plateau at 7.5 mg. The previous page's statement that absorption was linear and dose-proportional through 4 mg was not supported by the current label.

Why the Label Says “At Least 45 Minutes Before”

The labeled dose is 1.75 mg injected at least 45 minutes before anticipated sexual activity. That instruction sits near the observed Tmax but should not be converted into a guaranteed onset time. The dosage section says the duration of efficacy after each dose is unknown and the optimal administration window has not been fully characterized. Patients may determine timing with their prescriber based on experienced benefit and adverse effects.

Food does not directly govern absorption of an injected dose in the way it can for an oral tablet. That fact does not prove food can never influence symptoms such as nausea, and the label does not establish a meal-timing protocol for improving Vyleesi absorption.

Distribution: Protein Binding and Apparent Volume

The FDA-reported human serum protein binding is 21%. Mean volume of distribution after one subcutaneous dose is 25.0 L, with a standard deviation of 5.8 L.

Low protein binding can make displacement interactions less likely than they are for a highly bound medicine, but binding percentage alone is not enough to declare that all displacement interactions are impossible. The clinically emphasized interaction in the label is different: Vyleesi can slow gastric motility and alter the absorption of oral drugs.

The label does not quantify human brain concentrations or give a human blood-brain-barrier penetration percentage. Mechanistic descriptions should therefore distinguish receptor pharmacology from measured human tissue distribution.

Metabolism: Hydrolysis of a Cyclic Peptide

Bremelanotide is a synthetic cyclic peptide containing seven amino acids. The metabolism section of the label says its primary metabolic pathway involves multiple hydrolyses of the amide bonds of the cyclic peptide.

That is different from claiming that a named set of circulating fragments has been proved inactive in patients or that every cytochrome P450 and transporter interaction has been excluded. The current public label does not use those broad claims as the basis for prescribing. A source-checked summary can accurately say hydrolysis is primary without extending the evidence beyond the regulator's wording.

Elimination: Half-Life, Clearance, and Recovery

After one subcutaneous dose, the mean terminal half-life is approximately 2.7 hours, with a range of 1.9 to 4.0 hours. Mean apparent clearance is 6.5 L/hour, with a standard deviation of 1.0 L/hour. Both values appear in the current pharmacokinetic table and narrative.

In a radiolabeled study, 64.8% of total radioactivity was recovered in urine and 22.8% in feces. “Total radioactivity” is not synonymous with 64.8% unchanged parent drug. The prior page incorrectly described the urinary amount as parent drug plus specified fragments even though the label reports recovery by radioactivity.

A 2.7-hour mean half-life implies substantial decline in plasma concentration over roughly five half-lives, but it does not prove that every pharmacodynamic effect ends at the same time. The transient blood-pressure and heart-rate changes usually resolved within 12 hours in the clinical studies described by the label.

Kidney Impairment: Exposure Rises as eGFR Falls

The current renal-impairment data report the following AUC changes after a single dose:

• Mild renal impairment (eGFR 60 to 89 mL/min/1.73 m²) / 1.2-fold exposure
• Moderate renal impairment (eGFR 30 to 59 mL/min/1.73 m²) / 1.5-fold exposure
• Severe renal impairment (eGFR below 30 mL/min/1.73 m²) / 2-fold exposure

No dose adjustment is recommended for mild to moderate renal impairment. The label advises caution in severe renal impairment because increased exposure may increase the incidence or severity of adverse effects such as nausea and vomiting. The previous article incorrectly said severe renal impairment had not been studied and understated the moderate increase as about 40%.

Liver Impairment: Current FDA Values

After a single subcutaneous dose, AUC increased 1.2-fold in mild hepatic impairment (Child-Pugh A, score 5 to 6) and 1.7-fold in moderate hepatic impairment (Child-Pugh B, score 7 to 9). The effect of severe hepatic impairment was not studied in the current label.

No dose adjustment is recommended for mild to moderate hepatic impairment. The label advises caution in severe hepatic impairment because greater exposure could increase adverse effects. The previous page's 30% moderate-hepatic AUC increase and 44% Cmax increase did not match the current label's 1.7-fold AUC value.

The label does not recommend a lower improvised dose for organ impairment. The approved autoinjector delivers a fixed 1.75 mg dose, so organ-function decisions center on labeled cautions, individual risk, and whether treatment is appropriate.

Oral-Drug Interactions: Gastric Motility Is the Key

Vyleesi may slow gastric emptying and reduce the rate or extent of absorption of oral medicines. Clinical pharmacology studies did not find a clinically relevant effect for most tested oral drugs, except naltrexone and indomethacin. The drug-interaction section turns those findings into practical instructions rather than a universal spacing interval.

Oral Naltrexone

Vyleesi may significantly decrease systemic exposure to orally administered naltrexone. The label says patients should avoid Vyleesi with an oral naltrexone-containing product intended to treat alcohol or opioid addiction because naltrexone treatment failure could have serious consequences. Naltrexone is an avoid combination in this setting, not an FDA “contraindication” listed in section 4; the formal contraindications are uncontrolled hypertension and known cardiovascular disease.

Other Time-Sensitive Oral Medicines

The label advises avoiding Vyleesi when an oral medicine depends on reaching a threshold concentration for effectiveness, with antibiotics given as an example. It also says patients should consider discontinuing Vyleesi if it delays an oral medicine whose rapid onset is important, with indomethacin as an example. It does not prescribe a universal one- or two-hour staggering rule for triptans, analgesics, or anxiolytics.

Pharmacodynamics Are Not the Same as ADME

Pharmacokinetics describes what the body does to the drug. Pharmacodynamics describes what the drug does to the body. For Vyleesi, transient blood-pressure elevation, heart-rate reduction, nausea, and focal hyperpigmentation are clinically important pharmacodynamic effects, but they should not be used as substitutes for measured distribution or metabolism data.

The FDA warning section reports maximal average increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after a dose, with a heart-rate reduction of up to 5 beats per minute. Values usually returned to baseline within 12 hours. Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease.

What the Dose Limits Actually Reflect

Patients should not administer more than one dose within 24 hours, and more than eight doses per month is not recommended. The current dosing rationale is broader than “the half-life prevents accumulation.” Consecutive doses can add to blood-pressure effects, and more frequent monthly dosing increases the risk of focal hyperpigmentation and the amount of time each month during which blood pressure is elevated. Few phase 3 participants used more than eight doses per month.

The label also says to discontinue after eight weeks if symptoms have not improved. That stop rule is based on clinical response, not a pharmacokinetic laboratory threshold.

Corrected PK Summary for Clinicians and Patients

The most defensible Vyleesi PK summary is compact:

• Rapid, near-complete absorption after subcutaneous injection
• Median Tmax of about 1 hour, without a guaranteed onset or duration of effect
• Mean Cmax 72.8 ng/mL and AUC 276 hour-ng/mL
• Less than dose-proportional concentrations over the studied range
• 21% serum protein binding and mean 25.0 L distribution volume
• Peptide-bond hydrolysis as the primary metabolic pathway
• Mean half-life 2.7 hours and clearance 6.5 L/hour
• Radiolabeled recovery of 64.8% in urine and 22.8% in feces
• Higher exposure with renal or hepatic impairment
• Clinically important absorption interactions driven by slowed gastric motility

This version stays within measured human data and current regulator language. It does not depend on fabricated plasma thresholds, invented clinician quotations, unrelated PubMed records, or unsupported claims about weight, race, brain distribution, CYP panels, transporters, and next-day event rates.